| Biological Functions of Autophagy Genes: A Disease Perspective | Cell | 2019 | 896 |
| Macrophages and Metabolism in the Tumor Microenvironment | Cell Metabolism | 2019 | 374 |
| Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study | Journal of Clinical Oncology | 2019 | 364 |
| ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease† | Annals of Oncology | 2019 | 298 |
| Genomic characterization of metastatic breast cancers | Nature | 2019 | 256 |
| Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice | Nature Medicine | 2019 | 164 |
| Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence | Cancer Treatment Reviews | 2019 | 163 |
| The tumor suppressor protein p53 and the ferroptosis network | Free Radical Biology and Medicine | 2019 | 159 |
| Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer | Journal of Clinical Oncology | 2019 | 154 |
| Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines | European Journal of Cancer | 2019 | 152 |
| NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial | Lancet Oncology, The | 2019 | 148 |
| Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer | JAMA Oncology | 2019 | 147 |
| Clockophagy is a novel selective autophagy process favoring ferroptosis | Science Advances | 2019 | 137 |
| Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial | Lancet Oncology, The | 2019 | 136 |
| Alternate Day Fasting Improves Physiological and Molecular Markers of Aging in Healthy, Non-obese Humans | Cell Metabolism | 2019 | 131 |
| Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028 | Gynecologic Oncology | 2019 | 118 |
| Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors | Clinical Cancer Research | 2019 | 110 |
| Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors | Journal of Thoracic Oncology | 2019 | 106 |
| Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer | Journal of Experimental Medicine | 2019 | 105 |
| Crizotinib-induced immunogenic cell death in non-small cell lung cancer | Nature Communications | 2019 | 95 |
| Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade | Cell Research | 2019 | 91 |
| The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? | Annals of Oncology | 2019 | 82 |
| Efficacy of PI3K inhibitors in advanced breast cancer | Annals of Oncology | 2019 | 78 |
| Surgery in reference centers improves survival of sarcoma patients: a nationwide study | Annals of Oncology | 2019 | 76 |
| Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study | Journal of Clinical Oncology | 2019 | 74 |
